BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) CEO Jean Jacques Bienaime Sells 5,000 Shares of Stock

BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) CEO Jean Jacques Bienaime sold 5,000 shares of the business’s stock in a transaction dated Thursday, January 13th. The shares were sold at an average price of $87.86, for a total value of $439,300.00. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink.

Jean Jacques Bienaime also recently made the following trade(s):

  • On Wednesday, December 15th, Jean Jacques Bienaime sold 6,000 shares of BioMarin Pharmaceutical stock. The stock was sold at an average price of $82.71, for a total transaction of $496,260.00.
  • On Wednesday, December 1st, Jean Jacques Bienaime sold 1,500 shares of BioMarin Pharmaceutical stock. The shares were sold at an average price of $87.22, for a total transaction of $130,830.00.

BMRN stock opened at $90.22 on Friday. BioMarin Pharmaceutical Inc. has a fifty-two week low of $71.59 and a fifty-two week high of $92.17. The business’s 50-day moving average is $86.24 and its two-hundred day moving average is $81.34. The company has a debt-to-equity ratio of 0.25, a quick ratio of 3.03 and a current ratio of 4.49. The company has a market cap of $16.56 billion, a price-to-earnings ratio of 1,127.75, a P/E/G ratio of 2.90 and a beta of 0.49.

BioMarin Pharmaceutical (NASDAQ:BMRN) last posted its quarterly earnings data on Tuesday, October 26th. The biotechnology company reported ($0.20) EPS for the quarter, topping the consensus estimate of ($0.25) by $0.05. BioMarin Pharmaceutical had a return on equity of 2.02% and a net margin of 0.86%. The firm had revenue of $408.74 million for the quarter, compared to the consensus estimate of $435.29 million. During the same quarter last year, the company earned $0.29 earnings per share. The business’s revenue for the quarter was down 14.3% compared to the same quarter last year. Equities analysts predict that BioMarin Pharmaceutical Inc. will post 0.29 earnings per share for the current year.

A number of analysts recently commented on the company. Wedbush reaffirmed an “outperform” rating and issued a $152.00 price target on shares of BioMarin Pharmaceutical in a research note on Thursday, October 28th. JPMorgan Chase & Co. increased their target price on BioMarin Pharmaceutical from $129.00 to $135.00 and gave the stock an “overweight” rating in a research report on Monday, November 22nd. SVB Leerink restated a “buy” rating on shares of BioMarin Pharmaceutical in a research report on Thursday, December 2nd. Truist upped their price target on BioMarin Pharmaceutical from $125.00 to $135.00 in a research note on Monday, January 10th. Finally, Piper Sandler raised their price objective on BioMarin Pharmaceutical from $119.00 to $121.00 and gave the company an “overweight” rating in a research report on Thursday, October 28th. Four research analysts have rated the stock with a hold rating and twelve have given a buy rating to the company’s stock. Based on data from MarketBeat, BioMarin Pharmaceutical presently has an average rating of “Buy” and a consensus target price of $110.76.

Several large investors have recently added to or reduced their stakes in BMRN. Spire Wealth Management grew its holdings in BioMarin Pharmaceutical by 59.7% during the 4th quarter. Spire Wealth Management now owns 377 shares of the biotechnology company’s stock valued at $33,000 after buying an additional 141 shares in the last quarter. Commonwealth Equity Services LLC grew its holdings in BioMarin Pharmaceutical by 0.5% during the 2nd quarter. Commonwealth Equity Services LLC now owns 31,626 shares of the biotechnology company’s stock valued at $2,638,000 after buying an additional 156 shares in the last quarter. Bbva USA grew its holdings in BioMarin Pharmaceutical by 20.5% during the 3rd quarter. Bbva USA now owns 934 shares of the biotechnology company’s stock valued at $72,000 after buying an additional 159 shares in the last quarter. CIBC Private Wealth Group LLC grew its holdings in BioMarin Pharmaceutical by 0.3% during the 2nd quarter. CIBC Private Wealth Group LLC now owns 62,270 shares of the biotechnology company’s stock valued at $5,196,000 after buying an additional 169 shares in the last quarter. Finally, IndexIQ Advisors LLC grew its holdings in BioMarin Pharmaceutical by 5.7% during the 3rd quarter. IndexIQ Advisors LLC now owns 3,151 shares of the biotechnology company’s stock valued at $244,000 after buying an additional 169 shares in the last quarter. Hedge funds and other institutional investors own 94.15% of the company’s stock.

About BioMarin Pharmaceutical

BioMarin Pharmaceutical, Inc engages in the development and commercialization of therapies for people with serious and life-threatening rare diseases and medical conditions. Its pipeline products include Valoctocogene roxaparvovec, Vosoritide, and BMN 307. The company was founded by John C. Klock, Christopher M.

Recommended Story: Special Purpose Acquisition Company (SPAC)

Insider Buying and Selling by Quarter for BioMarin Pharmaceutical (NASDAQ:BMRN)

Receive News & Ratings for BioMarin Pharmaceutical Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for BioMarin Pharmaceutical and related companies with MarketBeat.com's FREE daily email newsletter.